JPMorgan Chase & Co. Has $56.17 Million Stake in Xenon Pharmaceuticals Inc. $XENE

JPMorgan Chase & Co. increased its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 11.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,399,033 shares of the biopharmaceutical company’s stock after buying an additional 142,452 shares during the quarter. JPMorgan Chase & Co.’s holdings in Xenon Pharmaceuticals were worth $56,171,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in XENE. Elevation Point Wealth Partners LLC acquired a new position in Xenon Pharmaceuticals in the 2nd quarter valued at $32,000. Danske Bank A S acquired a new stake in shares of Xenon Pharmaceuticals during the 3rd quarter worth $32,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Xenon Pharmaceuticals during the 3rd quarter worth $39,000. Osaic Holdings Inc. increased its position in shares of Xenon Pharmaceuticals by 541.4% in the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 1,034 shares during the period. Finally, L1 Capital Pty Ltd bought a new position in shares of Xenon Pharmaceuticals in the second quarter worth $41,000. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ:XENE opened at $55.17 on Friday. Xenon Pharmaceuticals Inc. has a one year low of $26.74 and a one year high of $63.95. The company has a market cap of $4.59 billion, a price-to-earnings ratio of -12.65 and a beta of 0.91. The firm has a 50 day simple moving average of $44.79 and a 200 day simple moving average of $42.37.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same period in the previous year, the company earned ($0.84) EPS. As a group, analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Insider Activity at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, insider Christopher John Kenney sold 1,410 shares of the stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $77,874.30. Following the completion of the transaction, the insider directly owned 7,069 shares in the company, valued at approximately $390,420.87. This trade represents a 16.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Ian Mortimer sold 7,308 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $55.23, for a total value of $403,620.84. Following the sale, the chief executive officer directly owned 19,923 shares in the company, valued at $1,100,347.29. The trade was a 26.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 336,707 shares of company stock valued at $19,622,565 in the last 90 days. 4.07% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on XENE shares. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Xenon Pharmaceuticals from $56.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. HC Wainwright raised their target price on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the company a “buy” rating in a report on Tuesday, March 10th. Bank of America reiterated a “buy” rating on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Wedbush lowered their price target on Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating for the company in a report on Monday. Finally, Jefferies Financial Group set a $100.00 price objective on Xenon Pharmaceuticals in a research report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $71.88.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.